Psychopharmacology 3.1

Overview of Alzheimer's Disease Model in Animal Research
  • Importance of Modeling: Understanding Alzheimer's through animal models helps translate findings to human cases.
Alzheimer’s Disease Statistics
  • Current Prevalence: Over 4.5 million people affected; numbers rising.
  • Age Factor: 1 in 10 individuals over 65 years, nearly 50% over 85 years affected.
  • Cause of Death: Alzheimer’s is the fourth leading cause; often not immediately fatal but leads to other health complications.
Symptoms of Alzheimer’s Disease
  • Cognitive Dysfunction: Memory loss as the primary symptom, accompanied by:
    • Decline in performing routine tasks.
    • Disorientation and coordination loss.
    • Lack of concentration, social withdrawal, and language skills deterioration.
  • Behavioral Changes: Can include aggression, weight loss, depression, and apathy.
  • Progressive Nature: Irreversible damage and progression over time noted.
Neurobiology of Alzheimer’s Disease
  • Neuronal Loss: Primarily in the hippocampus and entorhinal cortex.
  • Cognitive Decline Mapping: Normal aging results in slow decline; Alzheimer’s shows distinct phases:
    • Mental decline assessed through various disease stages: mild, moderate, and severe.
Pathological Changes
  • Brain Structure Changes: Observations show shrinkage of the cerebral cortex, hippocampus, and enlargement of ventricles.
  • First Symptoms: Confusion and memory loss attributed to early neuronal death.
Diagnosis and Biomarkers
  • Assessment Tools: Cognitive tests, blood tests, MRI scans provide indication but definitive diagnosis requires autopsy to find:
    • Neurofibrillary tangles.
    • Neuritic plaques caused by proteins (tau and beta-amyloid).
  • Associated Dysfunction: Reduction in acetylcholine levels linked to cholinergic dysfunction.
Animal Models for Research
  • Types of Models: Focus on both pathology and behavior, including:
    • Transgenic Models: Often categorize based on beta-amyloid or tau.
    • Pharmacological Models: Scopolamine induces deficits similar to Alzheimer's cognitive dysfunction, helping to formulate potential treatments.
  • Learning Tasks: Water maze provides insight into spatial learning and memory affected in Alzheimer's patients.
Experimental Approaches
  • Behavioral Testing: Short and long-term memory tasks are critical in assessing cognitive decline:
    • Delayed match to sample tasks in water maze.
    • Effective use of compounds like scopolamine and rivastigmine to observe changes.
  • Co-Morbidity Models: Research shows combining beta-amyloid and scopolamine enhances memory impairment.
Environmental Factors and Alzheimer's
  • Potential Environmental Risks: Aluminum, microplastics, and metals as possible contributors to degeneration seen in Alzheimer’s.
Conclusion and Future Directions
  • Animal Testing Goals: Aim is to validly represent Alzheimer’s pathology and symptoms to better test potential treatments. Further research is ongoing in this area with various model types.